Related Experiment Videos
[Tuberculosis among patients treated with TNF-alpha blockers]
Inbal Fuchs-Polychuck1, Lone Sølling Avnon, Mahmoud Abu-Shakra
1Department of Family Medicine, Soroka University Medical Center, Ben-Gurion University of the Negev Beer Sheva, Israel.
Harefuah
|April 28, 2007
Summary
Tumor necrosis factor alpha (TNF) blocking agents can increase the risk of latent tuberculosis infection (LTBI) reactivation. Guidelines recommend screening and prophylactic therapy for patients starting TNF blockade.
Area of Science:
- Immunology
- Infectious Diseases
- Pharmacology
Context:
- Biologic drugs targeting tumor necrosis factor alpha (TNF) are effective for chronic inflammatory diseases.
- TNF blockers are associated with an increased risk of tuberculosis (TB) reactivation.
- Existing international guidelines offer strategies for TB screening and prophylaxis in patients receiving TNF inhibitors.
Purpose:
- To review the risk of TB reactivation in patients treated with TNF blockers.
- To outline the role of TNF-alpha in TB pathogenesis.
- To summarize current protocols for minimizing TB risk during TNF blockade.
Summary:
- Treatment with TNF-blocking agents is linked to a higher risk of latent tuberculosis infection (LTBI) reactivation.
- This review examines the specific risks and the role of TNF-alpha in TB pathogenesis.
- It also details current strategies and guidelines for preventing TB reactivation in patients undergoing TNF blockade therapy.
Impact:
- Informing clinical practice regarding the safe use of TNF blockers.
- Highlighting the need for standardized TB screening and management protocols.
- Contributing to patient safety by mitigating the risk of severe infectious complications.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:29Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:31Pulmonary Tuberculosis III
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
01:26Pulmonary Tuberculosis IV
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:23Tuberculosis
Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...